To lead in any field comes with the
requirement to be a ‘change agent.’ As
we pursue our plans to lead the way in
Personalized Cancer Medicine, our team
is embracing change in every area of
patient care, and our scientific research
team has built strength in important
new areas including epigenetics,
immune therapy, computational biology
and clinical genomics.
The way in which our physicians
diagnose cancer is undergoing a major
transformation as we integrate new
technology that allows us to sequence
and study the DNA of each patient’s
tumour. This will allow us to distinguish
a lung tumour that responds to a
particular drug from one that won’t.
While our teams for each of the
established treatment modalities—
surgery, radiation and targeted drug
therapy—maintain their global
leadership and ensure their expertise is
shared across the country and the world,
we are introducing a new treatment
modality—cellular immune therapy.
The possibility of training our immune
system to recognize and eradicate
tumour cells is being tested
today
at
Princess Margaret Cancer Centre.
Your support is also enabling us to
innovate in two other areas very
important to cancer patients and
survivors—psychosocial support and
palliative care. Without hospice and
palliative care provided by trained
specialists, people living with cancer can
suffer severe pain and avoidable distress.
Constant re-inventing and upgrading
is required to conquer cancer in our
lifetime, and we thank you for helping
to fund these major enhancements
through your support of the
BILLION
DOLLAR CHALLENGE.
Every innovation is getting us closer
A message from Dr. Benjamin Neel and Dr. Mary
Gospodarowicz
Dr. Benjamin Neel
Research Director
Princess Margaret Cancer Centre/UHN
Dr. Mary Gospodarowicz
Medical Director
Princess Margaret Cancer Centre/UHN
